# HCA Healthcare, Inc.: Form 10-Q for the period ended Sep 30, 2018

- Company: [HCA Healthcare, Inc.](/companies/hca.md) (CIK 860730)
- Form: 10-Q
- Filed: 2018-11-06
- Accepted by EDGAR: Nov 6, 2018, 16:48 ET
- Period: 2018-09-30
- Accession: 0001193125-18-319640
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/860730/000119312518319640/d635258d10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/860730/000119312518319640/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2018-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2018-07-01 to 2018-09-30 | $11.45bn | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Revenue | 9 months, 2018-01-01 to 2018-09-30 | $34.40bn | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Interest expense | 3 months, 2018-07-01 to 2018-09-30 | $442.0m | us-gaap:InterestExpense |
| Interest expense | 9 months, 2018-01-01 to 2018-09-30 | $1.31bn | us-gaap:InterestExpense |
| Income tax | 3 months, 2018-07-01 to 2018-09-30 | $173.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2018-01-01 to 2018-09-30 | $702.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2018-07-01 to 2018-09-30 | $759.0m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2018-01-01 to 2018-09-30 | $2.72bn | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2018-07-01 to 2018-09-30 | $2.15 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2018-01-01 to 2018-09-30 | $7.65 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2018-07-01 to 2018-09-30 | $2.20 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2018-01-01 to 2018-09-30 | $7.82 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2018-07-01 to 2018-09-30 | 353,639,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2018-01-01 to 2018-09-30 | 356,124,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2018-01-01 to 2018-09-30 | $4.59bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2018-01-01 to 2018-09-30 | $2.42bn | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 9 months, 2018-01-01 to 2018-09-30 | $366.0m | us-gaap:PaymentsOfDividends |
| Share repurchases | 9 months, 2018-01-01 to 2018-09-30 | $1.20bn | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2018-09-30 | $578.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2018-09-30 | $10.01bn | us-gaap:AssetsCurrent |
| Total assets | at 2018-09-30 | $38.04bn | us-gaap:Assets |
| Current liabilities | at 2018-09-30 | $6.23bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2018-09-30 | $41.77bn | us-gaap:Liabilities |
| Long-term debt | at 2018-09-30 | $32.92bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2018-09-30 | $191.0m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2018-09-30 | −$5.61bn | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 1,651 characters.

During the quarter ended September 30, 2018, we repurchased 2,517,742 shares of our common stock at an average price of $120.26 per share through market purchases pursuant to the $2 billion share repurchase program authorized during October 2017. At September 30, 2018, we had $607 million of repurchase authorization available under the October 2017 authorization.

The following table provides certain information with respect to our repurchases of common stock from July 1, 2018 through September 30, 2018 (dollars in millions, except per share amounts).

| Period | Total Number of Shares Purchased | Average Price Paid per Share | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs | Approximate Dollar Value of Shares That May Yet Be Purchased Under Publicly Announced Plans or Programs |
| --- | ---: | ---: | ---: | ---: |
| July 1, 2018 through July 31, 2018 | 1,095,236 | $106.68 | 1,095,236 | $793 |
| August 1, 2018 through August 31, 2018 | 709,923 | $128.18 | 709,923 | $702 |
| September 1, 2018 through September 30, 2018 | 712,583 | $133.25 | 712,583 | $607 |
| Total for third quarter 2018 | 2,517,742 | $120.26 | 2,517,742 | $607 |

On October 29, 2018, our Board of Directors declared a quarterly dividend of $0.35 per share on our common stock payable on December 28, 2018 to stockholders of record on December 3, 2018. Future declarations of quarterly dividends and the establishment of future record and payment dates are subject to the final determination of our Board of Directors. Our ability to declare future dividends may also from time to time be limited by the terms of our debt agreements.

## Market risk

As filed, 186 characters.

The information called for by this item is provided under the caption “Market Risk” under Item 2, “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”

## Controls and procedures

As filed, 847 characters.

### Evaluation of Disclosure Controls and Procedures

HCA’s management, with participation of HCA’s chief executive officer and chief financial officer, has evaluated the effectiveness of HCA’s disclosure controls and procedures as of September 30, 2018. Based on that evaluation, HCA’s chief executive officer and chief financial officer concluded that HCA’s disclosure controls and procedures were effective as of September 30, 2018. There were no material changes in HCA’s internal control over financial reporting during the third quarter of 2018.

### Changes in Internal Control Over Financial Reporting

During the period covered by this report, there have been no changes in our internal control over financial reporting that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.

## Risk factors

As filed, 448 characters.

Reference is made to the factors set forth under the caption “Forward-Looking Statements” in Part I, Item 2 of this quarterly report on Form 10-Q and other risk factors described in our annual report on Form 10-K for the year ended December 31, 2017, which are incorporated herein by reference. There have not been any material changes to the risk factors previously disclosed in our annual report on Form 10-K for the year ended December 31, 2017.

Filed Nov 6, 2018.
Source: SEC EDGAR, the filing index for accession 0001193125-18-319640. Last ingested by Listed: Nov 11, 2026, 03:15 ET. No prices; not investment advice.
